Literature DB >> 21487788

Soluble vascular endothelial growth factor (VEGF) receptor-1 inhibits migration of human monocytic THP-1 cells in response to VEGF.

Cansheng Zhu1, Zhaojun Xiong, Xiaohong Chen, Zhengqi Lu, Guoyu Zhou, Dunjing Wang, Jian Bao, Xueqiang Hu.   

Abstract

OBJECTIVE: We aimed to investigate the regulation and contribution of vascular endothelial growth factor (VEGF) and sFlt-1(1-3) to human monocytic THP-1 migration.
MATERIALS AND METHODS: Ad-sFlt-1/FLAG, a recombinant adenovirus carrying the human sFlt-1(1-3) (the first three extracellular domains of FLT-1, the hVEGF receptor-1) gene, was constructed. L929 cells were infected with Ad-sFlt-1/FLAG and the expression of sFlt-1 was detected by immunofluorescent assay and ELISA. Corning(®) Transwell(®) Filter Inserts containing polyethylene terephthalate (PET) membranes with pore sizes of 3 μm were used as an experimental model to simulate THP-1 migration. Five VEGF concentrations (0, 0.1, 1, 10 and 100 ng/ml), four concentrations of sFlt-1(1-3)/FLAG expression supernatants (0.1, 1, 10 and 100 ng/ml), and monocyte chemoattractant protein-1 (MCP-1, 10 ng/ml) were used to test the ability of THP-1 cells to migrate through PET membranes.
RESULTS: The sFlt-1(1-3) gene was successfully recombined into Ad-sFlt-1/FLAG. sFlt-1(1-3) was expressed in L929 cells transfected with Ad-sFlt-1/FLAG. THP-1 cell migration increased with increasing concentrations of VEGF, while cell migration decreased with increasing concentrations of sFlt1(1-3)/FLAG. sFlt1(1-3)/FLAG had no effect on MCP-1-induced cell migration.
CONCLUSIONS: This study demonstrated that VEGF is able to elicit a migratory response in THP-1 cells, and that sFlt-1(1-3) is an effective inhibitor of THP-1 migration towards VEGF.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21487788     DOI: 10.1007/s00011-011-0332-7

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  25 in total

1.  Upregulation of vascular growth factors in multiple sclerosis: correlation with MRI findings.

Authors:  Jen Jen Su; Manabu Osoegawa; Takeshi Matsuoka; Motozumi Minohara; Masahito Tanaka; Takaaki Ishizu; Futoshi Mihara; Takayuki Taniwaki; Jun-ichi Kira
Journal:  J Neurol Sci       Date:  2005-12-27       Impact factor: 3.181

Review 2.  Multiple sclerosis--the plaque and its pathogenesis.

Authors:  Elliot M Frohman; Michael K Racke; Cedric S Raine
Journal:  N Engl J Med       Date:  2006-03-02       Impact factor: 91.245

3.  Mapping of the sites for ligand binding and receptor dimerization at the extracellular domain of the vascular endothelial growth factor receptor FLT-1.

Authors:  B Barleon; F Totzke; C Herzog; S Blanke; E Kremmer; G Siemeister; D Marmé; G Martiny-Baron
Journal:  J Biol Chem       Date:  1997-04-18       Impact factor: 5.157

Review 4.  Insights into the molecular pathogenesis of progression in multiple sclerosis: potential implications for future therapies.

Authors:  Jaime Imitola; Tanuja Chitnis; Samia J Khoury
Journal:  Arch Neurol       Date:  2006-01

5.  Genomic organization of the flt-1 gene encoding for vascular endothelial growth factor (VEGF) receptor-1 suggests an intimate evolutionary relationship between the 7-Ig and the 5-Ig tyrosine kinase receptors.

Authors:  K Kondo; S Hiratsuka; E Subbalakshmi; H Matsushime; M Shibuya
Journal:  Gene       Date:  1998-02-27       Impact factor: 3.688

6.  Characterization of vascular permeability factor/vascular endothelial growth factor receptors on mononuclear phagocytes.

Authors:  H Shen; M Clauss; J Ryan; A M Schmidt; P Tijburg; L Borden; D Connolly; D Stern; J Kao
Journal:  Blood       Date:  1993-05-15       Impact factor: 22.113

7.  Macrophages in multiple sclerosis.

Authors:  W Brück; N Sommermeier; M Bergmann; U Zettl; H H Goebel; H A Kretzschmar; H Lassmann
Journal:  Immunobiology       Date:  1996-10       Impact factor: 3.144

8.  Blockade of vascular endothelial growth factor suppresses experimental restenosis after intraluminal injury by inhibiting recruitment of monocyte lineage cells.

Authors:  Kisho Ohtani; Kensuke Egashira; Ken-ichi Hiasa; Qingwei Zhao; Shiro Kitamoto; Minako Ishibashi; Makoto Usui; Shujiro Inoue; Yoshikazu Yonemitsu; Katsuo Sueishi; Masataka Sata; Masabumi Shibuya; Kenji Sunagawa
Journal:  Circulation       Date:  2004-10-11       Impact factor: 29.690

9.  Treatment with anti-CR3 antibodies ED7 and ED8 suppresses experimental allergic encephalomyelitis in Lewis rats.

Authors:  I Huitinga; J G Damoiseaux; E A Döpp; C D Dijkstra
Journal:  Eur J Immunol       Date:  1993-03       Impact factor: 5.532

10.  Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration.

Authors:  M Clauss; M Gerlach; H Gerlach; J Brett; F Wang; P C Familletti; Y C Pan; J V Olander; D T Connolly; D Stern
Journal:  J Exp Med       Date:  1990-12-01       Impact factor: 14.307

View more
  4 in total

1.  Vascular endothelial growth factor promotes fibrosis resolution and repair in mice.

Authors:  Liu Yang; Junghee Kwon; Yury Popov; Gabriella B Gajdos; Tamas Ordog; Rolf A Brekken; Debabrata Mukhopadhyay; Detlef Schuppan; Yan Bi; Douglas Simonetto; Vijay H Shah
Journal:  Gastroenterology       Date:  2014-02-04       Impact factor: 22.682

2.  Temporal phenotypic features distinguish polarized macrophages in vitro.

Authors:  David W Melton; Linda M McManus; Jonathan A L Gelfond; Paula K Shireman
Journal:  Autoimmunity       Date:  2015-03-31       Impact factor: 2.815

3.  Decreased expression of ADAMTS-1 in human breast tumors stimulates migration and invasion.

Authors:  Vanessa M Freitas; Jônatas Bussador do Amaral; Thaiomara A Silva; Emerson S Santos; Flávia R Mangone; João de Jesus Pinheiro; Ruy G Jaeger; Maria A Nagai; Gláucia Maria Machado-Santelli
Journal:  Mol Cancer       Date:  2013-01-05       Impact factor: 27.401

4.  Effect of AMPK signal pathway on pathogenesis of abdominal aortic aneurysms.

Authors:  Le Yang; Lin Shen; Peixian Gao; Gang Li; Yuxiang He; Maohua Wang; Hua Zhou; Hai Yuan; Xing Jin; Xuejun Wu
Journal:  Oncotarget       Date:  2017-10-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.